(Reuters) - Vaccine developer Inovio Pharmaceuticals Inc said the company and its partner GeneOne Life Science Inc will start testing its experimental Ebola vaccine in humans in the first half of 2015. Inovio's shares were up 7 percent at $10.48 in late morning trading on the Nasdaq. Inovio said animal studies showed that vaccinated guinea pigs and mice survived after being exposed to the deadly virus. The studies showed that the experimental vaccine could also benefit the patients by protecting them from weight loss, apart from fighting the virus. ... via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment